TITLE： Molecular Design and Synthesis at the Interface of Chemistry, Biology and Medicine
SPEAKER： Iwao Ojima，Distinguished Professor, State University of New York-Stony Brook
TIME： July 23 (Thursday) PM16:00
LOCATION： Fifth-floor Lecture Hall, Chemistry Building A (化学A楼演讲厅)
INVITER： Prof. Wanbin Zhang (张万斌教授)
 

报告人Professor Iwao Ojima简介：
Dr. Iwao Ojima received his B.S. in 1968, M.S. in 1970 and Ph.D. in 1973 (with Prof. Naoki Inamoto) all at the University of Tokyo. He worked for ten years at Sagami Institute of Chemical Research as a Senior Research Fellow and Group Leader. He is currently Distinguished Professor of Chemistry and Director of the Institute of Chemical Biology and Drug Discovery at State University of New York-Stony Brook, where he has been a faculty member since 1983. Professor Ojima’s many awards have included Guggenheim fellow (1995), ACS Arthur C. Cope Scholar Award (1994), ACS Emanuel B. Hershberg Award for Important Discoveries in Medicinally Active Substances (2001), the 51st Chemical Society of Japan Award for distinguished achievements by the Chemical Society of Japan (1999), and the NYSTAR Faculty Development Award by New York State Office of Science (2002). Professor Ojima has been invited for more than 10 lectureships such as Boehringer-Ingelheim Distinguished Lecturer, Bristol-Meyers Squibb Distinguished Lecturer, George Lesher Lecturer and Negishi-Brown Lecturer. He was elected to AAAS in 1997, New York Academy of Sciences in 2000 and ACS Medicinal Chemistry Hall of Fame in 2006.

Professor Ojima has made great contributions to the discovery and development of new and potent taxoid anticancer agents, anti-thrombotic agents, cardiovascular agents and enzyme inhibitors. His group discovered second-generation taxoids and advanced second-generation taxoids that exhibit excellent activities against multidrug resistant (MDR) cancer cell lines. Professor Ojima discovered silylformylation, carbonylation and silylcarbocyclization reactions and new chiral ligands/catalysts such as chiral monodentate phosphorus ligands. He has 300+ publications and 150+ patents based on his research.